Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
April 25, 2024 07:00 ET
|
Eyenovia, Inc.
Company announces results from a Phase IV study of Mydcombi designed to characterize the efficacy and duration of the lowest deliverable dose (one 8µL spray per eye) Also announces upcoming ARVO...
Eyenovia Announces Updated Strategy and Corporate Priorities to Focus on Shareholder Value Generation and Immediate Commercial Opportunities
April 08, 2024 07:00 ET
|
Eyenovia, Inc.
Company focusing on multi-billion dollar opportunity in pediatric progressive myopia represented by MicroPine, with interim analysis planned for 4Q 2024 and a potential NDA to the FDA in...
Eyenovia to Feature its Suite of Commercial Products and the Optejet Dispenser at Upcoming National Eyecare Meetings
April 03, 2024 07:00 ET
|
Eyenovia, Inc.
Company to demonstrate Mydcombi™ and Avenova® and Share Data for Clobetasol Propionate Ophthalmic Suspension 0.05% at the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting,...
Eyenovia Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
March 18, 2024 16:05 ET
|
Eyenovia, Inc.
Announced FDA approval of clobetasol propionate ophthalmic suspension 0.05% for post-operative pain and inflammation following ocular surgery Reacquired development and commercialization rights to...
NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals
March 13, 2024 07:00 ET
|
Eyenovia, Inc.
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion...
Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
March 11, 2024 07:00 ET
|
Eyenovia, Inc.
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release financial...
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
March 05, 2024 08:00 ET
|
Eyenovia, Inc.
Approval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery Eyenovia...
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
February 13, 2024 07:00 ET
|
Eyenovia, Inc.
Redwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi NEW YORK, Feb. ...
Eyenovia Re-Acquires Development and Commercialization Rights to MicroPine in the U.S. and Canada
January 16, 2024 07:00 ET
|
Eyenovia, Inc.
MicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007 Part of corporate...
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
November 13, 2023 16:05 ET
|
Eyenovia, Inc.
Acquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals Announced FDA approval of Coastline...